Single-molecule chemiluminescent photosensitizer for a self-activating and tumor-selective photodynamic therapy of cancer

Eur J Med Chem. 2019 Dec 1:183:111683. doi: 10.1016/j.ejmech.2019.111683. Epub 2019 Sep 6.

Abstract

While photodynamic therapy is known for significant advantages over conventional cancer therapies, its dependence on light has limited it to treating tumors on or just under the skin or on the outer lining of organs/cavities. Herein, we have developed a single-molecule photosensitizer capable of intracellular self-activation and with potential tumor-selectivity due to a chemiluminescent reaction involving only a cancer marker. Thus, the photosensitizer is directly chemiexcited to a triplet excited state capable of generating singlet oxygen, without requiring either a light source or any catalyst/co-factor. Cytotoxicity assays involving the photosensitizer show significant toxicity toward tumor cells, even better than reference drugs, while not inducing toxicity toward normal cells. This work provides a proof-of-concept for a novel type of photosensitizer that eliminates the current restrictions that photodynamic therapy presents regarding tumor size and localization.

Keywords: Breast cancer; Cancer; Chemiluminescence; Coelenterazine; Photodynamic therapy; Photosensitizer; Prostate cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Computer Simulation
  • Humans
  • Imidazoles / chemistry*
  • Light
  • Neoplasms / drug therapy*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / chemistry*
  • Photosensitizing Agents / pharmacology
  • Proof of Concept Study
  • Pyrazines / chemistry*
  • Pyrazines / pharmacology
  • Singlet Oxygen / metabolism
  • Thermodynamics

Substances

  • Imidazoles
  • Photosensitizing Agents
  • Pyrazines
  • Singlet Oxygen
  • coelenterazine